Regorafenib Regulates AD Pathology, Neuroinflammation, and Dendritic Spinogenesis in Cells and a Mouse Model of AD

Regorafenib Regulates AD Pathology, Neuroinflammation, and Dendritic Spinogenesis in Cells and a Mouse Model of AD

The oral multi-target kinase inhibitor regorafenib, which targets the oncogenic receptor tyrosine kinase (RTK), is an effective therapeutic for patients with advanced gastrointestinal stromal tumors or metastatic colorectal cancer. However, whether regorafenib treatment has beneficial effects on neu...

Full description

Bibliographic Details
Main Authors: Kyung-Min Han, Ri Jin Kang, Hyongjun Jeon, Hyun-ju Lee, Ji-Soo Lee, HyunHee Park, Seong Gak Jeon, Kyoungho Suk, Jinsoo Seo, Hyang-Sook Hoe
Format: Article
Language:English
Published: MDPI AG 2020-07-01
Series:Cells
Subjects:
regorafenib
neuroinflammation
dendritic spine
amyloid beta
tau
aging
Online Access:https://www.mdpi.com/2073-4409/9/7/1655

Internet

https://www.mdpi.com/2073-4409/9/7/1655

Similar Items